USTEKINUMAB (Stelara) prior authorization at Healthfirst
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
Healthfirst requires Interleukin-12 Antagonist prior-authorization documentation for USTEKINUMAB (Stelara): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return in 30 days; if denied, prescribers and members have 60 days to appeal.
The PA criteria you'll need to meet
Healthfirst reviews USTEKINUMAB (Stelara) prior authorizations against its medical policy for Interleukin-12 Antagonist. Healthfirst-specific context: Provider-sponsored not-for-profit; largest Medicaid MCO in NY State (~1.8M members). Owned by ~30 NY hospital systems. NY DFS oversight. NY State Fair Hearing is escalation path for Medicaid denials; commercial appeals go to DFS external appeal program.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in Interleukin-12 Antagonist
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- Healthfirst's medical policy URL referenced in the cover letter
Healthfirst's common denial patterns
Pre-empting these patterns in the initial submission cuts rework and shortens time-to-approval:
- NY State Medicaid Managed Care carve-outs
- Behavioral health prior auth
- Dental/vision coordination
- Out-of-network non-emergency
USTEKINUMAB (Stelara)-specific denial patterns and context
Across payers (not just Healthfirst), USTEKINUMAB (Stelara)draws a distinct set of denial reasons rooted in the drug's label, REMS, and competitive landscape:
- Step therapy requiring TNF-inhibitor first (plaque psoriasis, PsA, Crohn's, UC)
- Site-of-care reduction for IV induction dose
- Biosimilar substitution mid-treatment
- Prior auth missing PASI or HBI documentation
Brand: Stelara. IL-12/23 inhibitor. Loss of exclusivity 2023; FDA-approved biosimilars now include Wezlana (interchangeable), Selarsdi, Pyzchiva, Imuldosa, Otulfi, Steqeyma. Plans aggressively switching to biosimilar in 2025.
Manufacturer patient-assistance program: Janssen CarePath — relevant when a Healthfirst denial sticks and the patient needs bridge access while appealing.
How Healthfirst approaches Biologic drugs (mAbs and biosimilars) PAs
Healthfirst's Biologic drugs (mAbs and biosimilars) reviewer typically requires documented failure or contraindication to a conventional DMARD or step-1 biologic (often a TNF inhibitor or biosimilar) plus disease-activity scoring before approving USTEKINUMAB (USTEKINUMAB). Pharmacy-benefit review for USTEKINUMAB (USTEKINUMAB) at Healthfirst is routed through in-house pharmacy benefits for Medicaid MCO members. The 30-day standard review window starts when the prior-authorization request is received with all required documentation — incomplete packets pause the clock and add 5-10 days to time-to-approval, after which the 60-day internal-appeal window begins from the denial date. Healthfirst's utilization-management vendor (Carelon, eviCore, OptumRx, or in-house) sets the step-therapy ladder — appeals that cite ACR, AAD, or AGA guideline language directly to the medical director shorten escalation. Healthfirst is domiciled in NY, so unresolved appeals escalate to the NY insurance department's external-review program for fully-insured policies (self-funded ERISA plans route to the DOL EBSA instead). Provider-sponsored not-for-profit; largest Medicaid MCO in NY State (~1.
If the PA is denied
Healthfirst gives prescribers and members 60 days to file an internal appeal. Standard appeal decisions return within 30 days. Submit through the provider portal (https://hfdocs.healthfirst.org) with the same packet plus a peer-reviewed citation supporting USTEKINUMAB (Stelara)for the patient's indication.
Helping a patient appeal the denial directly? See the consumer guide: How to appeal a Healthfirst denial on DenialHelp.
Contact Healthfirst
- Provider portal: https://hfdocs.healthfirst.org
Frequently asked questions
What documentation does Healthfirst need for USTEKINUMAB (Stelara) prior auth?
Healthfirst's typical PA packet for USTEKINUMAB (Stelara): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis. For Interleukin-12 Antagonist, expect clinical-criteria documentation specific to this class.
What's the turnaround time at Healthfirst?
Standard USTEKINUMAB (Stelara) PA decisions at Healthfirst: 30 days. Urgent / expedited (member's life or function at risk): 72 hours under 45 CFR §147.136.
What does Healthfirst most often reject USTEKINUMAB (Stelara) for?
Across Healthfirst's book the common rejection patterns include: NY State Medicaid Managed Care carve-outs; Behavioral health prior auth; Dental/vision coordination. For USTEKINUMAB (Stelara) specifically, expect step-therapy challenges and indication-restriction reviews when the use is at the edge of the FDA label or off-label.
What prior failures does Healthfirst typically require before approving USTEKINUMAB (USTEKINUMAB)?
Healthfirst's biologics step-therapy ladder for most indications begins with a conventional DMARD (methotrexate, sulfasalazine, leflunomide) or topical/inhaled first-line, then a step-1 biologic (typically a TNF inhibitor or adalimumab biosimilar), then the requested agent. Document trial duration (≥12 weeks for most biologics), dosing reached, and reason for discontinuation (inadequate response by disease-activity score, intolerance, or contraindication). For USTEKINUMAB (USTEKINUMAB), attach the specific disease-activity instrument Healthfirst accepts (e.g., DAS28, PASI 75, HBI, Mayo) — appeals with raw symptom narrative but no scored instrument carry higher denial rates. Pharmacy-benefit handling is routed through in-house pharmacy benefits for Medicaid MCO members. External-review escalation for Healthfirst fully-insured policies sits with the NY insurance department.
How do I prep for a peer-to-peer with Healthfirst on USTEKINUMAB (Stelara)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
Generate the USTEKINUMAB (Stelara) PA packet
Open ApprovalHelp — generate a USTEKINUMAB (Stelara) prior-auth packet tailored to Healthfirst's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com